CSF tau microtubule-binding region identifies pathological changes in primary tauopathies.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36424467.
- Also identified by DOI 10.1038/s41591-022-02075-9 and PMC identifier 9800273.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Despite recent advances in fluid biomarker research in Alzheimer's disease (AD), there are no fluid biomarkers or imaging tracers with utility for diagnosis and/or theragnosis available for other tauopathies. Using immunoprecipitation and mass spectrometry, we show that 4 repeat (4R) isoform-specific tau species from microtubule-binding region (MTBR-tau<sub>275</sub> and MTBR-tau<sub>282</sub>) increase in the brains of corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), frontotemporal lobar degeneration (FTLD)-MAPT and AD but decrease inversely in the cerebrospinal fluid (CSF) of CBD, FTLD-MAPT and AD compared to control and other FTLD-tau (for example, Pick's disease). CSF MTBR-tau measures are reproducible in repeated lumbar punctures and can be used to distinguish CBD from control (receiver operating characteristic area under the curve (AUC) = 0.889) and other FTLD-tau, such as PSP (AUC = 0.886). CSF MTBR-tau<sub>275</sub> and MTBR-tau<sub>282</sub> may represent the first affirmative biomarkers to aid in the diagnosis of primary tauopathies and facilitate clinical trial designs.
Medical subject headings
- Tauopathies
- Alzheimer Disease
- Frontotemporal Lobar Degeneration
- Frontotemporal Dementia